Cargando…

The Application of Nanobody in CAR-T Therapy

Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Chaolemeng, Gao, Quanli, Li, Lin-Lin, Han, Lu, Zhang, Bingxiang, Ding, Yijin, Song, Zongpei, Zhang, Ruining, Zhang, Jishuai, Wu, Xian-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914546/ https://www.ncbi.nlm.nih.gov/pubmed/33567640 http://dx.doi.org/10.3390/biom11020238

Ejemplares similares

Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
por: Han, Lu, et al.
Publicado: (2021)

Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph(+) B cell acute lymphoblastic leukemia
por: Han, Lu, et al.
Publicado: (2022)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

Nanobody Based Dual Specific CARs
por: De Munter, Stijn, et al.
Publicado: (2018)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Applications of nanobodies in brain diseases
por: Zheng, Fang, et al.
Publicado: (2022)

Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
por: De Munter, Stijn, et al.
Publicado: (2020)

A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor
por: Sun, Shuyang, et al.
Publicado: (2023)

Advances in Developing CAR T-Cell Therapy for HIV Cure
por: Qi, Jinxin, et al.
Publicado: (2020)

Nanobody Conjugates for Targeted Cancer Therapy and Imaging
por: Kang, Wei, et al.
Publicado: (2021)

IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
por: Fanuzzi, Mia, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Nanobody: a promising toolkit for molecular imaging and disease therapy
por: Bao, Guangfa, et al.
Publicado: (2021)

Applications of nanobodies in plant science and biotechnology
por: Wang, Wenyi, et al.
Publicado: (2020)

Radiolabeling Strategies of Nanobodies for Imaging Applications
por: Küppers, Jim, et al.
Publicado: (2021)

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
por: Temple, William C, et al.
Publicado: (2023)

Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies
por: Chen, Yu-Lei, et al.
Publicado: (2023)

Recombinant expression of nanobodies and nanobody-derived immunoreagents
por: de Marco, Ario
Publicado: (2020)

Nanobodies: Chemical Functionalization Strategies and Intracellular Applications
por: Schumacher, Dominik, et al.
Publicado: (2018)

Affimers and nanobodies as molecular probes and their applications in imaging
por: Cordell, Paul, et al.
Publicado: (2022)

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia
por: Cheng, Jiali, et al.
Publicado: (2023)

CAMEL NANOBODY-BASED B7-H3 CAR-T CELLS WITH HIGH EFFICACY AGAINST SOLID TUMORS
por: Li, Dan, et al.
Publicado: (2023)

Identification and characterization of blocking nanobodies against human CD70: Identification and characterization of blocking nanobodies
por: Zhang, Xin, et al.
Publicado: (2022)

Nanobodies as novel agents for disease diagnosis and therapy
por: Siontorou, Christina G
Publicado: (2013)

Revolutionizing antiviral therapy with nanobodies: Generation and prospects
por: Mustafa, Mujahed I., et al.
Publicado: (2023)

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
por: Ho, Jin-Yuan, et al.
Publicado: (2021)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

Nanobody-based immunosensing methods for safeguarding public health
por: Zhang, Jiarong, et al.
Publicado: (2021)

Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies
por: Zuo, Jing, et al.
Publicado: (2017)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Application of Single-Domain Antibodies (“Nanobodies”) to Laboratory Diagnosis
por: Pillay, Tahir S., et al.
Publicado: (2021)

Research progress and applications of nanobody in human infectious diseases
por: Mei, Yaxian, et al.
Publicado: (2022)

Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
por: Ruiz-López, Eduardo, et al.
Publicado: (2022)

Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library
por: Yan, Junrong, et al.
Publicado: (2015)

Immuno-targeting the multifunctional CD38 using nanobody
por: Li, Ting, et al.
Publicado: (2016)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d86njsa4s0bhfeqfhmj6dme5q0